Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors

NCT06484985 is registered in ClinicalTrials.gov with Axter Therapeutics (Beijing) Co., Ltd as lead sponsor.

NCT NCT06484985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06484985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase I Safety Study of AXT-1003 in Subjects With Advanced Malignant Tumors
Lead sponsor
Axter Therapeutics (Beijing) Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 4, 2024
Completion date
September 30, 2027
Enrollment
78 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, non-hodgkin lymphoma